Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss the treatment choice between targeted therapy and immunotherapy in a patient with an EGFR Mutation and high PDL-1.
Case Based Panel Discussion - Choosing Between Targeted Therapy and Immunotherapy in a Patient with an EGFR Mutation and High PDL-1 Expression
Drs Zofia Piotrowska, H. Jack West, and Taofeek Owonikoko sit down to discuss a series of case-based scenarios. In this video, the doctors discuss a frail patient with metastatic squamous NSCLC with low tumor PD-L1 expression, and the best treatment approach for this patient.
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), presents Molecular Diagnostic Testing and Next Generation Sequencing in Lung Cancer webinar series.
, , , ,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
Dr. Vamsidhar Velcheti with the Cleveland Clinic joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses MET as a target in advanced non-small cell lung cancer.
- 1 of 33
- View More
Head & Neck Cancers Frequently Asked Questions Written by Joshua Bauml, MD September 2017 What is it? “Head and neck cancer” is an umbrella term...
Malignant Hematology Progress in understanding DNA changes in lymphoma has already provided improved and highly sensitive tests for detecting this...
Over the next few days, about 30,000 oncologists and other cancer care professionals, along with a growing number of patient advocates, are...
New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It's a Poor Choice for Initial Treatment
The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...
Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.
- 1 of 151
- View More
Mother-in-Law was diagnosed with NSCLC and after a blood biopsy, doctor is recommending Osimertinib. I tried searching on the main page, but it wasn'...
March 20, 2018 at 2:04 pm #1294118 JimC Forum Moderator JimC Forum Moderator If you’d like to stay informed about the latest GRACE developments, you...
I’m a 40yr old female with a smoking history of 20+ years. I have chronic brown phlegm (for years) with little to no coughing. I had a chest X-ray in...